CA
NZ
UK
AU
IND
US
Morgan Stanley Finance LLC filed a free writing prospectus on November 9, 2026, disclosing terms for Contingent Income Auto-Callable Securities linked to Novo Nordisk A/S American depositary shares, with a maturity date of December 29, 2027.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed Amendment No. 2 to a Schedule 13G with the SEC on November 9, 2026, disclosing their beneficial ownership of Class A Common Stock in Definitive Healthcare Corp as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed Amendment No. 2 to a Schedule 13G with the SEC, disclosing beneficial ownership of common stock in Karyopharm Therapeutics Inc. as of September 30, 2026.
A Form 144 notice of proposed sale was filed on November 9, 2026, disclosing that Binod Patwari, a former officer of Linde PLC, intends to sell 2,500 shares of Linde common stock through Fidelity Brokerage Services LLC.
Morgan Stanley Finance LLC filed a Free Writing Prospectus to Preliminary Pricing Supplement No. 20,005 on November 9, 2026, disclosing the terms of Worst-of INDU, RTY and SPX Trigger Jump Securities due December 6, 2033.
Tracx Logis Ltd. filed a Form 8-A on November 9, 2026, to register its Ordinary Shares, no par value, for listing on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.
Globa Terra Acquisition Corporation filed Definitive Additional Materials on November 9, 2026, disclosing that its Extraordinary General Meeting of Shareholders was adjourned the same day after receiving insufficient votes on a proposal to extend the deadline for completing a Business Combination.
Electronic Servitor Publication Network Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $139,445 for the nine months ended on that date and a total stockholders' deficit of $2,798,081.
Vertex, Inc. officer Ryan J. Leib filed a Form 144 notice of proposed sale of securities with the SEC on November 9, 2026, covering 6,963 Class A shares with an aggregate market value of $121,051.76.
Tiziana Life Sciences Ltd filed a Form 6-K with the SEC on November 9, 2026, furnishing additional context on positive topline results from its Phase 2a INFORM-MS trial following a Key Opinion Leader investor call held the same day.
Please wait processing your request...